Similar articles

Abstract: Objective: To evaluate clinical, quality of life (QoL) and medical cost outcomes in patients with symptomatic reflux esophagitis (RE) receiving different "triple combination therapy". Methods: A multicenter medical effectiveness trial conducted in 10 hospitals of 5 regions in Zhejiang Province. 248 patient-volunteers were assigned to 8 weeks of "triple combination therapy" with Lansoprazole plus Cisapride and Sucralfate or Ranitidine plus Cisapride and Sucralfate. Main outcomes assessment included symptoms scale scores, RE severity, QoL at baseline and 8 weeks. Medical cost data were collected with cost analysis questionnaire. Results: (1) More Lansoprazole group patients noted RE symptoms resolution than Ranitidine group (92.3% vs 78.4%, P<0.01). There was no striking difference between two groups in RE healing rate (90.8% vs 82.9%, P>0.05). (2) RE significantly impaired QoL of patients (P<0.001).Compared with Ranitidine group, QoL in Lansoprazole group had significant improvement (rate of "good" QoL 64.5% vs 45.6%, P<0.01). (3)There was close correlation between symptomic effectiveness and QoL rating scale in both the Lansoprazole and Ranitidine group (P<0.01, r=0.235 and 0.353 respectively). There were no statistical difference of medical cost between the two groups (P>0.05). Conclusion: RE significantly impaired QoL of patients. "Triple combination therapies" can significantly improve RE symptoms and QoL. Lansoprazole combination therapy was more cost-effective than Ranitidine combination group.

[1]Bloom, B.S.,Hillman, A.L. and Lammont, B., 1995. Omeprazole or ranitidine plus metoclopramide for patients with severe esophagitis: a cost-effetiveness analysis. Pharmacoeconomic, 8:343-349.

[2]Devault, K.R. and Castell, D.O., 1995. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch. Intern. Med., 155:2165-2173.

[3]Hawden, C.W.,Castell, D.O. and Cohen, S., 1995. The rational for continuous maintenance treatment of reflux esophagitis. Arch. Intern. Med., 155:1465-1471.

[4]Mathias, S.D., Castell, D.O. and Elkin, E.P., 1996. Health-related quality of life of patients with acute erosive reflux esophagitis. Dis Sci., 41:2123-2123.

[5]McDougall, N.I., Johnston, B.T. and Kee, F., 1996. Natural history of reflux oesophagitis: a 10-year followup of its effect on patients symptomatology and quality of life. Gut., 38:481-486.

[6]Mckenna, C.J., Mills, J.G. and Gooduin, C., 1995. Combination of ranitidine and cisapride in the treatment of reflux oeseophagitis. Eur. J. Gastroenterol Hepatol, 7: 817-822.

[7]Pan, G.Z., Xu, G.M. and Guo, H.P., 1999. An epidemiologic study on gastroesophageal reflux symptoms in Beijing and Shanghai. Chinese Journal of Digestion, 19:223-226(in Chinese with English abstract).

[8]Vic, Velanovich, 2000.Quality of life and severity of symptoms in gastro-oesophageal reflux disease: a clinical review. Eur. J. Surg., 166:516-525.

[9]Vigneri, S., Termini, R. and Leandro, G., 1995. A comparison of five maintenance therapies for reflux esophagitis. N. Eng. J. Med., 333:1106-1110.

[10]Yang, L., Li, C.Y. and Wu, J.C., 1997. Study of effectiveness of ranitidine plus cisapride compared ranitidine for GERD. Chinese Journal of Endoscopy, 3:9-10(in Chinese with English abstract).

[11]Zagari, M.,Villa, K.F. and Freston, J.W., 1995. Proton pump inhibitors versus H₂-receptor anatagonists fot the treatment of erosive gastroesophageal reflux disease: A cost comparative study. Am. J. Man. Care., 1:247-255.